Reports of cognitive decline, symptom worsening and brain atrophy in bipolar disorder (BD) suggest that the disease progresses over time. The worsening neuropathology may involve excitotoxicity and neuroinflammation. We determined protein and mRNA levels of excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from 10 BD patients and 10 age-matched controls. The brain tissue was matched for age, postmortem interval and pH. The results indicated statistically significant lower protein and mRNA levels of the N-methyl-Daspartate receptors, NR-1 and NR-3A, but significantly higher protein and mRNA levels of interleukin (IL)-1b, the IL-1 receptor (IL-1R), myeloid differentiation factor 88, nuclear factorkappa B subunits, and astroglial and microglial markers (glial fibrillary acidic protein, inducible nitric oxide synthase, c-fos and CD11b) in postmortem frontal cortex from BD compared with control subjects. There was no significant difference in mRNA levels of tumor necrosis factor alpha or neuronal nitric oxide synthase in the same region. These data show the presence of excitotoxicity and neuroinflammation in BD frontal cortex, with particular activation of the IL-R cascade. The changes may account for reported evidence of disease progression in BD and be a target for future therapy.
Introduction
Bipolar disorder (BD) is a severe psychiatric disease characterized by repeated manic and depressive episodes. Reports of symptom worsening, cognitive decline and progressive brain atrophy suggest that the disease is progressive and has a neurodegenerative component. Progression is consistent with reports of structural, metabolic and signaling abnormalities in postmortem brain from BD patients, [1] [2] [3] [4] [5] [6] and with evidence of excitotoxicity and neuroinflammation in BD. [7] [8] [9] [10] Animal studies have shown that both processes are associated with increased levels of proinflammatory cytokines, reactive oxygen radicals and nitric oxide in brain, and may be accompanied by upregulation of brain arachidonic acid signaling markers. [11] [12] [13] Expression levels of enzymes involved in arachidonic acid metabolism, including arachidonate-selective cytoplasmic phospholipase A 2 (cPLA 2 ), secretory phospholipase A 2 , and cyclooxygenase-2, were found elevated in postmortem frontal cortex from BD patients compared with control subjects. 14 A number of markers have been shown to be altered by neuroinflammation and excitotoxicity. For example, chronic administration of subconvulsive doses of N-methyl-D-aspartate (NMDA) decreased rat brain expression of the NMDA receptor (NR) subunits, NR-1 and NR-3A, 11 and upregulated mRNA and activity of cPLA 2 and of one of its transcription factors, activator protein-2 (AP-2). 12 Chronic NMDA also upregulated rat brain protein and mRNA levels of neuroinflammatory markers, interleukin-1 beta (IL1b), tumor necrosis factor-alpha (TNFa), glial fibrillary acidic protein (GFAP) and inducible nitric oxide synthase (iNOS). 12 Binding of IL-1 to the IL-1 receptor (IL-1R) recruits IL-R-associated kinase to the receptor complex through its association with the IL-1R accessory protein 13 and with adaptor protein myeloid differentiation factor (MyD88). 15, 16 Upon recruitment, IL-Rassociated kinase is highly phosphorylated and subsequently dissociates from the receptor complex to interact with TNF receptor-associated factor 6, 17 which in turn is involved in activation of nuclear I kappa kinase and nuclear factor-kappa B (NF-kB) activation 18 ( Figure 1 ). TNFa can regulate cPLA 2 and cyclooxygenase-2 expression in a mitogen-activated protein kinase-dependent manner in various cell types. [19] [20] [21] Activation of IL-1R by IL-1 triggers activation of its cascade, increasing expression of cPLA 2 , 13, 15, 16 secretory phospholipase A 2 , 16 cyclooxygenase-2, 22 GFAP [19] [20] [21] and iNOS through the activation of transcription factors, AP-2 or NF-kB, in mouse astrocytes and other cell types. In response to an excitotoxic insult, iNOS 23 and the immediate early gene, c-fos, are expressed and considered as specific biomarkers of excitotoxicity. 24 To further clarify the possible contributions of neuroinflammation and excitotoxicity in BD, in this study we measured protein and mRNA levels of markers of these processes in the postmortem frontal cortex from BD patients and control subjects, matched for age, postmortem interval (PMI) and pH. Among others, we measured expression of NR subunits, of IL1b, IL-1R and MyD88, and markers of activated glia and astroglia. We chose these markers to focus on possible changes in the IL-1 R cascade (Figure 1) . We studied the frontal cortex because earlier studies indicated structural, metabolic and signaling abnormalities in this area in BD patients. [1] [2] [3] [4] [5] [6] 14 Materials and methods ) did not differ significantly between the BD and control groups: age (years, control: 43 ± 3.5 vs BD: 49 ± 7.2), PMI (hours, control: 27±1.5 vs BD: 21±3.0) and brain pH (control: 6.6 ± 0.16 vs BD: 6.7 ± 0.09). The BD patients were exposed to various psychotropic medications, as shown earlier. 26 Preparation of membrane, nuclear and cytoplasmic extracts Membrane, cytoplasmic and nuclear extracts were prepared from frozen tissue samples as described. 11 Briefly, the tissue was homogenized in 20 mM Tris HCl (pH 7.5) and 0.2 mM EDTA buffer containing a cocktail of protease inhibitors (Roche, Indianapolis, IN, USA). The suspension was centrifuged at 100,000 g for 1 h at 4 1C and the supernatant (S1), containing mostly cytosolic constituents, was removed. The pellet was re-suspended in the earlier mentioned buffer containing 0.1% Triton-X 100, and incubated for 1 h at 4 1C. This mixture was centrifuged at 100 000 g for 1 h at 4 1C. The resulting supernatant (S2), containing membrane constituents, was removed. Protein concentrations of cytosolic and membrane extracts were determined using a Bio-Rad protein reagent (Bio-Rad, Hercules, CA, USA). Each membrane and cytosolic fraction was characterized using cadherin and tubulin antibodies.
Postmortem brain samples
Nuclear extracts were prepared from frozen tissue as described earlier. 27 The nuclear fraction was characterized by using lamin B antibody. Protein concentrations of cytoplasmic and nuclear extracts were determined using Bio-Rad Protein Reagent (Bio-Rad).
Western blot analysis Protein (50 mg) from the membrane, cytoplasmic and nuclear extracts was separated on 4-20% SDSpolyacrylamide gels (Bio-Rad). After electrophoresis, the proteins were transferred to a nitrocellulose membrane. Membrane protein blots were incubated overnight in Tris-buffered saline solution, containing 5% nonfat dried milk and 0.1% Tween-20, with specific primary antibodies (1:200 dilution) for the NR-1, NR-2A, NR-2B, NR-3A, IL-1R and cadherin (Cell Signaling, Beverly, MA, USA). Cytosolic protein cascade activation by IL-1b. Activation of the type I IL-1R by IL-1b leads to recruitment of interleukin receptor-associated kinase (IRAK) to the receptor complex through its association with the IL-1R accessory protein and an adaptor protein, myeloid differentiation factor 88 (MyD88). On association, IRAK becomes highly phosphorylated and subsequently dissociates from the receptor complex to interact with tumor necrosis factor receptor-associated factor 6 (TRAF6), which in turn is involved in nuclear I kappa kinase (NIK) and nuclear factor-kappa B (NF-kB) activation. Activator protein-2 (AP-2) transcription factor is also activated by IL-1b. GFAP, glial fibrillary acidic protein; sPLA 2 , secretory phospholipase A 2 ; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2.
blots were incubated similarly, but with primary antibodies (1:200 dilution) for IL-1b, MyD88, GFAP, iNOS, nNOS (neuronal nitric oxide synthase) and tubulin (Cell Signaling). Nuclear NF-kB p50 and NFkB p65 protein levels were determined using specific (1:200) primary antibodies (Cell Signaling). Membrane, cytoplasmic and nuclear protein blots were incubated with appropriate HRP-conjugated secondary antibodies (Bio-Rad) and visualized using a chemiluminescence reaction (Amersham, Piscataway, NJ, USA) on X-Ray film (Kodak, Rochester, NY, USA). Optical densities of immunoblot bands were measured using Alpha Innotech Software (Alpha Innotech, San Leandro, CA, USA) and were normalized to b-actin (Sigma, St. Louis, MO, USA). Experiments were carried out in duplicate for the 10 control and 10 BD brain samples. Mean density values were expressed as percent of control.
Total RNA isolation and real-time reverse transcriptase PCR Total RNA from brain and lipid-rich tissue was isolated using an RNeasy mini kit (Qiagen, Valencia, CA, USA). The RNA integrity number was measured using a Bioanalyzer (Agilent 2100 bioanalyzer, Santa Clara, CA, USA). The RNA integrity number values were 6.9 ± 0.4 for the control samples and BD 7.15 ± 0.5 (mean ± s.e.m.) for the BD samples. The cDNA (complementary DNA) was prepared from total RNA using a high capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA). Messenger RNA levels of NR-1, NR-2A, NR-2B, NR-3A, IL-1b, IL-1R, MyD88, TNFa GFAP, iNOS, nNOS, CD11b, p50, p65 and c-fos were measured by quantitative reverse transcriptase PCR, using an ABI PRISM 7000 sequence detection system (Applied Biosystems). Specific primers and probes for NR-1, NR-2A, NR-2B, NR-3A, IL-1b, IL-1R, MyD88, GFAP, iNOS, nNOS, CD11b, p50, p65 and c-fos were purchased from TaqMan gene expression assays (Applied Biosystems) and consisted of a 20 Â mix of unlabeled PCR primers and TaqMan minor groove binder probe (FAM (6-carboxy-fluorescein) dye labeled). The fold-change in gene expression was determined by the DDC T method. 27 Data were expressed as the relative level of the target gene in the BD tissue normalized to the endogenous control (b-globulin) and relative to the control (calibrator), as described earlier. 28 All experiments were carried out twice in triplicates with 10-10 independent samples, and the data were reported as relative expression.
Immunohistochemistry
Frozen tissue, held on a dry ice bed, was sectioned in a cryostat. The cut surface was immediately refrozen. One section was used for biochemical or molecular analysis, whereas the corresponding section was used for immunohistochemistry.
For immunohistochemistry, frozen sections were warmed to À20 1C from À80 1C storage conditions. Each section was gently raised to room temperature and immersion-fixed with 4% paraformaldehyde for 18 h and cyroprotected in 30% sucrose. The cryostat sections were air dried for 60 min, rinsed in 1 Â automation buffer (Biomedia Corp., Foster City, CA, USA). Sections were treated with 0.3% hydrogen peroxide to quench endogenous peroxidase activity, and then incubated for 1 h at room temperature with a monoclonal human leukocyte antigen-D-related antibody (1:750; MBL, Woburn, MA, USA). Sections were rinsed, incubated for 30 min at room temperature with secondary antibody (Vector Elite Kit, Burlingame, CA) and detected with DAB (diamino-benzidine) chromagen (Dako, Carpinteria, CA, USA). An antibody to GFAP was used to detect astrocytes. Staining was conducted on an IHC Omni-UltraMap HRP (Ventana Medical Systems, Tucson, AZ, USA). Sections were incubated with anti-GFAP (1:3500; Dako) for 32 min at room temperature, rinsed, incubated with OmniMap anti-Rb HRP for 16 min, and counter-stained with modified Harris hematoxylin. Images were collected using an Aperio Scanscope T2 Scanner (Aperio Technologies, Vista, CA, USA) and viewed using an Aperio Imagescope v. 6.25.0.1117. Images were rated by two independent scorers blind to subject classification. Samples were rank-ordered on the basis of the level of the glial responses and then clustered on the basis of the subject classification.
Statistical Analysis
Data are expressed as mean ± s.e.m. Statistical significance of means was calculated using a two-tailed unpaired t-test at P < 0.05. Pearson correlations were made between age, PMI and pH and mRNA levels of NR-1, NR-2A, NR-2B, NR-3A, IL-1, IL-1R, Myd88, GFAP, iNOS, NF-kB65, NF-kB50 and CD11B in postmortem frontal cortex from control subjects and BD patients, separately. Statistical significance was set at P < 0.05.
Results
Decreased protein and mRNA levels of NR-1 and NR-3A in frontal cortex from BD patients The mean protein levels of NR-1, NR-2A, NR-2B and NR-3A in postmortem BD brain were compared with the matched control brain. NR-1 and NR-3A protein levels were decreased significantly by 42% (P < 0.05) and 41% (P < 0.01), respectively, in BD brain when compared with control brain (Figures 2a and 2d) , whereas the mean NR-2A and NR-2B protein levels did not differ significantly between the groups (Figures 2b and 2c) . The mRNA levels of NR-1 and NR-3A were significantly decreased in BD compared with control brain by 0.42-fold (P < 0.01) and 0.46-fold (P < 0.01), respectively (Figures 2e and 2h) , whereas NR-2A and NR-2B mRNA levels were not significantly different (Figures 2f and 2g) .
Increased protein and mRNA levels of IL-1b, IL-1R and MyD88 in frontal cortex from BD patients As illustrated in Figure 3 , compared with control subjects, there were significantly elevated protein levels of the inflammatory cytokines, IL-1b (41%; P < 0.05), IL-R (41%;P < 0.05) and MyD88 (38%; P < 0.05) in frontal cortex from BD patients (Figures 3a-3c ). Significant increases also were seen and myeloid differentiation factor 88 (MyD88) (c) protein (with representative immunoblots) as percent of control in frontal cortex, from control (n = 10) and bipolar disorder (BD) (n = 10) subjects. Data are optical densities relative to that of b-actin. IL-1b (d), IL-1R (e) and MyD88 (f) mRNA levels in the frontal cortex from controls (n = 10) and BD patients (n = 10), measured using reverse transcriptase PCR. Data are normalized to the endogenous control (b-globulin) and expressed relative to the control (calibrator), using the DDC T method. Mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001.
in mRNA levels for IL-1b (2.2-fold; P < 0.01), IL-R (3.6-fold; P < 0.001) and MyD88 (3.6-fold; P < 0.01) (Figures 3d-3f ).
Increased nuclear protein and mRNA levels of p50 and p65 in frontal cortex from BD patients There were significant increases in nuclear protein and mRNA levels of p50 (45% and 0.8-fold, respectively) (Figures 4a-c; P < 0.05) and of p65 (62% and 1.4-fold, respectively) (P < 0.01, P < 0.001, Figures 4b-4d) in the BD brain.
Increased cell markers of astrocytes and microglia in frontal cortex from BD patients A significant increase was observed in the mean protein levels of GFAP (46%; P < 0.05) and of iNOS (37%; P < 0.05) in BD frontal cortex when compared with control frontal cortex (Figures 5a and 5b) . The increased protein levels were accompanied by significant increases in mRNA levels of GFAP (0.7-fold; P < 0.01) and iNOS (1.7-fold; P < 0.01) (Figures 5d and  5e ). However, there was no significant difference in the protein or mRNA level of nNOS (Figures 5c and  5f ). c-fos and CD11b protein and mRNA levels were significantly higher in BD brain when compared with control brain (Figures 6a-6d ).
There was no significant difference in TNFa mRNA level in the frontal cortex from BD patients ( Figure  6e ). The elevation in astrocyte and microglia markers was supported by immunohistochemical staining for both GFAP and HLD-A (Figure 6f) . In control tissue, GFAP þ astrocytes displayed fine fibrous processes, whereas in the BD tissue, hypertrophic GFAP þ astrocytes were detected. In BD tissue, furthermore, human leukocyte antigen-D-related antibody staining detected increased staining for process-bearing microglia displaying a thickening of processes.
Correlation data with brain variables
Pearson correlations between mRNA levels in control and BD brains with respect to PMI, age and pH, were Figure 4 Mean nuclear factor-kappa B (NF-kB) p50 (a) and NF-kB p65 (b) protein levels (with representative immunoblots) in frontal cortex from control (n = 10) and bipolar disorder (BD) (n = 10) subjects. Bar graphs are ratios of optical densities of NF-kB p50 or NF-kB p65 to that of bactin, expressed as percent of control. NF-kB p50 (c) and NF-kB p65 (d) mRNA in postmortem frontal cortex from the control (n = 10) and BD (n = 10) subjects, measured using reverse transcriptase PCR. Data are levels of NF-kB p50 and NF-kB p65 in BD normalized to the endogenous control (b-globulin) and relative to the control (calibrator), using the DDC T method. Mean±s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001. all statistically insignificant (P > 0.05) ( Table 1) . Mean values of the three parameters did not differ significantly between the patient and the control groups.
Discussion
This study showed a significant increase in excitotoxicity and neuroinflammatory markers in BD frontal cortex when compared with control frontal cortex. Decreased mean protein and mRNA levels of the NR1 and NR-3A subunits were accompanied by increased levels of markers of excitotoxicity, c-fos and iNOS mRNA. In addition, protein and mRNA levels of IL1b, IL-1R, MyD88 and NF-kB subunits (p50 and p65) in the same region were increased significantly. There was a significant increase in GFAP expression, and also in the level of CD11b mRNA (a marker of astrocyte and microglial activation) in postmortem frontal cortex from BD patients. Increases in protein and mRNA levels were associated with increased staining for GFAP and human leukocyte antigen-Drelated antibody in the same brain region from BD patients. However, there was no significant difference in nNOS or TNFa expression in postmortem frontal cortex from BD patients compared with control subjects. In sum, these results are consistent with a marked activation of the IL-1R cascade, which is characteristic of both systemic and local insults.
29,30
Involvement of excitotoxicity in BD Studies have shown that an excitotoxic insult caused by chronic NMDA administration decreased expression of NR subunits and increased levels of neuroinflammatory markers in rat brain. 11, 12 Similarly, we observed decreased expression of NR-1 and NR-3 subunits in the postmortem frontal cortex from BD patients. Excitotoxicity 23 in this study was indicated by the increased protein and mRNA levels of iNOS without a significant change in nNOS expression in the BD brain. Although this observation is not consistent with an earlier study 31 that reported an increase in nNOS in postmortem hippocampal region from BD patients, the difference may represent differences in the response between the different brain regions. Further, characterization of the BD frontal cortex revealed a significant increase in c-fos expression, a marker of excitotoxicity, 24, 32, 33 suggesting the presence of excitotoxicity in BD.
Consistent with our findings regarding the presence of excitotoxicity markers, earlier studies indicated an elevated brain glutamate/glutamine ratio in children and adults with BD. 8 Postmortem brains of BD patients displayed decreased levels of the NR subunits, NR-1, NR-2A and NR-3A. 9, 10 The mRNA levels of NR-1, NR-2A and NR-3A also were found to be decreased in the postmortem BD brain, as were concentrations of the NR-associated postsynaptic proteins, PSD-95 and SAP102. 34 Finally, gene variants of NR-1 and NR-2 have been linked to the disease. 10, 35, 36 These studies suggest that an increase in glutamate transmission is associated with decreased expression of NR subunits.
The observed differences in expression of the NMDA subunits in the BD brain indicate increased changes in NR activity. The NR stimulation by glutamate or by NMDA decreases NR1 expression, which we have observed earlier. 14, 37 Furthermore, in vitro studies indicate that the NR3A subunit coassembles with other subunits (NR-1, NR-2A or NR-2B) to form NRs with reduced activity and Ca 2 þ influx, 38, 39 whereas mice lacking the NR-3A subunit have increased NR activity. 40 Increased NMDA function could increase arachidonic acid signaling.
14 Rats given a daily subconvulsive dose of NMDA for 3 weeks showed reduced brain levels of NR-1 and NR-3A, increased arachidonic acid turnover in phospholipids, increased protein and mRNA levels of cPLA 2 and secretory phospholipase A 2 , increased AP-2 DNA binding activity and increased AP-2a and AP-2b protein in the frontal cortex.
14 Involvement of neuroinflammation in BD Interleukin 1 is a major cytokine responsible for inducing a number of proteins associated with inflammation. 41 Many of these responses are induced by the rapid activation of the transcription factor, NFkB, after signal transduction caused by IL-1b binding to the type I IL-1R. 42 Similarly, this study shows an increased protein and mRNA levels of IL-1b, IL-1R and MyD88 in BD brain, which may be responsible for the observed upregulated NF-kB transcription factor. The increase in NF-kB may also be responsible for increased expression of iNOS and GFAP, markers for astrocytes. The observed increase in GFAP expression in this study is not in line with other observations on BD brain, 43, 44 but this discrepancy may be because of regional differences or drug exposure. An earlier clinical study did indicate an increase in serum TNFa level in BD patients. 45 However, in this study we did not see a similar change in postmortem frontal cortex from BD patients.
The observed increases in neuroinflammatory markers in the BD brain 14 may have been induced, in part, by underlying process of excitotoxicity. Thus, chronic NMDA administration to rats upregulated neuroinflammatory markers, and cerebroventricular infusion of high lipopolysaccharide concentrations for weeks to months induced IL-1b, TNFa and amyloid precursor protein, leading to degeneration of hippocampal CA3 pyramidal neurons. 46 Cytokines associated with neuroinflammation can activate both cPLA 2 and secretory phospholipase A 2 at astrocytic cytokine receptors. [47] [48] [49] [50] None of the mRNA levels in either the BD or control brains was correlated significantly with PMI, brain pH or subject age, and mean values of these parameters did not differ significantly between the two groups. Nevertheless, the BD patients had been exposed to a variety of drugs not experienced by the control subjects, which may have confounded the results. Owing to their selective exposure, our findings may be related to differences in drug exposure, rather than being specific to the BD trait. Thus, future studies should examine arachidonic cascade markers in brains from patients with schizophrenia (to use a roughly comparable drug exposure as a control) or with unipolar (primary major) depression, or with Alzheimer's disease (to test for disease specificity). 51 In conclusion, markers of the excitotoxicity and neuroinflammation are significantly upregulated in postmortem frontal cortex from BD patients. Their upregulation might result in cell death, and account for the brain atrophy and cognitive decline that have been reported in BD patients. Our observations suggest that agents that attenuate excitotoxicity or neuroinflammation could prove beneficial for treating BD.
Chronic administration to rats of lithium, valproic acid, carbamazepine or lamotrigine, mood stabilizers that have been approved for treating BD, was reported to decrease the markers of brain arachidonic acid metabolism that had been shown to be upregulated in rat models of excitotoxicity and neuroinflammation, as well as in the BD brain. 12, 14 These markers include cPLA 2 and cyclooxygenase-2, and some of their transcription factors, AP-2 and NF-kB. Some of the mood stabilizers also prevented NMDA-and lipopolysaccharide-induced increases in arachidonic acid markers in rat brain. 12, [52] [53] [54] [55] This study supports the presence of excitotoxicity and neuroinflammation in BD.
